Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
necessitated the rapid development of antibody-based therapies and vaccines as …

The emerging new lineages of severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) have marked a new phase of coronavirus disease 2019 (COVID-19). Understanding …

SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angiotensin-
converting enzyme 2 (ACE2). Therefore, the receptor binding domain (RBD) of the S protein …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

The COVID-19 pandemic is a major threat to global health for which there are only limited
medical countermeasures, and we lack a thorough understanding of mechanisms of …

The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …